Abstract Background/aims: To identify factors associated with significant liver fibrosis in patients with type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD) and to inform clinical risk stratification. Methods: We retrospectively included adults hospitalized in the Department of Endocrinology, Nanjing Drum Tower Hospital, from January 2018 to December 2025 who had T2DM, MASLD, and vibration-controlled transient elastography (VCTE).
